Scynexis Inc SCYX

$5.12 -0.25 (-4.66%)

Valuation

Market cap
53,429,000
Revenue TTM
$20,600,000
Net income TTM
$-8,610,000
PE ratio
0.00
Forward PE
—
Profit margin
-41.80%
Debt to equity
0.00

Trading

Volume
132,400
Avg volume
325,954
Day's range
$5.09 – $5.51
Shares out
9,950,000
Stochastic %K
66%
Beta
1.06
Analysts
Strong Sell
Price target
$36.33

Price

Company profile

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fu...

Show more

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
201 884 5485
Website
https://www.scynexis.com
Address
1 Evertrust Plaza, 13th Floor, Jersey City, United States

Latest news

Stocktwits

MarketDegenerate Oct 3, 4:25 PM
$SCYX — This financing news is hard to overlook for a biotech this size. SCYNEXIS just secured a BARDA contract providing up to $214M in potential non-dilutive funding for antifungal candidate SCY-247. The initial ~$18.5M portion helps advance oral and IV versions toward Phase 2 in invasive candidiasis. Government-funded development significantly changes the financing equation here.
0 replies
RobbysInvestmentLLC Oct 2, 2:18 PM
$ADGM same playyy as $SCYX $NIVF $AMOD 🚀🚀🚀
0 replies
RobbysInvestmentLLC Oct 2, 1:31 PM
$ADGM should follow $SCYX $NIVF $AMOD 🚀🚀🚀
0 replies
RobbysInvestmentLLC Oct 2, 1:25 PM
$ADGM spiked to .18 yesterday today to .30 hottest theme off $SCYX $NIVF $AMOD 🚀🚀🚀🚀
0 replies
RobbysInvestmentLLC Oct 2, 1:10 PM
$ADGM big bidders this could be the next banger off $SCYX $NIVF $AMOD let’s goooo🚀🚀🚀🚀
0 replies
SDBiotechInvestor Oct 2, 1:09 PM
$SCYX market environment flipped today. Perfect setup for Monday data PR. Going in with > $8 cash/share.
0 replies
UKBullTrader Oct 2, 12:59 PM
$SCYX looks good for a nice climb upwards today. 😀
0 replies
smallpower17 Oct 1, 6:06 PM
$SCYX Realistically, what does this go to if GSK announces that they are going to start selling Brexafemme?
3 replies